Edesa Biotech, Inc. (EDSA) income statement
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.06+0.10 (+5.10%)
Close on Nov 18, 2026Market cap $19.86MP/E –Yield –
Edesa Biotech, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -99.6%
Financial strength
- Current ratio
- 2.76
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 263.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.25
- Dividend yield
- –
See a number that looks wrong?